Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Boston Medical Technologies: Private placement valued at $22.6 mil. brings to $38 mil. the total raised by the start-up since July 1998. Funds will be used for expansion efforts to meet "growing demand" for the Wakefield, Massachusetts firm's Anscore system for measuring diabetic patients' heart rate variability during physician office visits, BMT says. The non-invasive device was initially cleared via 510(k) in June 1999, with subsequent clearances in August 2000 and April 2001 expanding system parameters. "Extensive published clinical data reports that heart rate variability testing can be used as an indicator of autonomic nervous system dysfunction - a deadly but initially asymptomatic condition prevalent in people with diabetes," BMT explains. Prism Venture Partners led the third-round financing...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015041

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel